Researchers showed that COL4A3 was a significant predictive factor in a clinical trial involving 58 patients with advanced NSCLC and that patients with low COL4A3-expressing tumors had considerably longer median OS than those with high COL4A3-expressing tumors (44). Here, COL4A3 is linked to non-small cell lung carcinoma.